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The associations of the adiponectin (APM1) gene with
parameters of the metabolic syndrome are inconsistent. We
performed a systematic investigation based on fine-mapped
single nucleotide polymorphisms (SNPs) highlighting the
genetic architecture and their role in modulating adiponec-
tin plasma concentrations in a particularly healthy popula-
tion of 1,727 Caucasians avoiding secondary effects from
disease processes. Genotyping 53 SNPs (average spacing of
0.7 kb) in the APM1 gene region in 81 Caucasians revealed
a two-block linkage disequilibrium (LD) structure and
enabled comprehensive tag SNP selection. We found par-
ticularly strong associations with adiponectin concentra-
tions for 11 of the 15 tag SNPs in the 1,727 subjects (five P
values <0.0001). Haplotype analysis provided a thorough
differentiation of adiponectin concentrations with 9 of 17
haplotypes showing significant associations (three P val-
ues <0.0001). No significant association was found for any
SNP with the parameters of the metabolic syndrome. We
observed a two-block LD structure of APM1 pointing to-
ward at least two independent association signals, one
including the promoter SNPs and a second spanning the
relevant exons. Our data on a large number of healthy
subjects suggest a clear modulation of adiponectin concen-
trations by variants of APM1, which are not merely a
concomitant effect in the course of type 2 diabetes or
coronary artery disease. Diabetes 55:375–384, 2006
T
he metabolic syndrome is a cluster of disorders
with increasing prevalence mainly due to behav-
ioral risk factors (1). However, it remains to be
shown to what extent genetic components play a
role in the pathogenesis of this major health problem.
One of the most interesting candidate genes with re-
spect to the metabolic syndrome and type 2 diabetes is the
APM1 gene encoding adiponectin. Adiponectin plasma
concentrations play an important role in modulating insu-
lin sensitivity and glucose homeostasis (2–4) and have
been found to be decreased in humans with type 2
diabetes (5), coronary artery disease (6), and obesity (7).
Morbidly obese subjects loosing weight following a gastric
partition surgery consequently exhibited a raise in adi-
ponectin concentrations, while glucose and insulin levels
decreased (8). Injection experiments in various animal
models revealed that adiponectin is sufficient to reduce
blood glucose levels without affecting plasma insulin lev-
els, suggesting that adiponectin directly improves insulin
sensitivity (9–11). Low plasma adiponectin levels are
further associated with other components of the metabolic
syndrome, such as hypertension (12) and dyslipidemia
(13).
APM1 maps to chromosome 3q27, a region with evi-
dence for linkage with type 2 diabetes (14) and the
metabolic syndrome (15). However, despite the key role of
adiponectin plasma concentrations in the pathogenesis of
the major metabolic disorders and an abundance of liter-
ature regarding the APM1 gene locus, direct evidence for
the association of certain SNPs with disease outcomes are
still conflicting or are not in line with associations pub-
lished for adiponectin concentrations. One of the reasons
for this may be that most of the studies to date were
designed to estimate associations with a certain disease
outcome in a case-control design and a limited number of
subjects with measured adiponectin concentrations.
It has thus been the aim of this study to provide a
systematic investigation involving high-density SNPs cov-
ering the APM1 gene in a large group of healthy Cauca-
sians in order to clarify whether the gene variants show
associations with plasma adiponectin concentrations and
parameters of the metabolic syndrome independently
from the development of obesity, type 2 diabetes, or
coronary artery disease.
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RESEARCH DESIGN AND METHODS
The Salzburg Atherosclerosis Prevention Program in Subjects at High Individ-
ual Risk (SAPHIR) study is an observational study conducted in 1999–2002
involving 1,770 healthy unrelated subjects (663 women 50–70 years of age and
1,107 men 40–60 years of age). The differential age range between the sexes
was chosen to match the cardiovascular risk, which is lower for women when
compared with men of the same age but matches the risk of men aged 10
years. Study participants were recruited by health screening programs in large
companies in and around the city of Salzburg. All individuals were of
Caucasian origin. Subjects with established coronary artery, cerebrovascular,
or peripheral arterial disease; congestive heart failure; valvular heart disease;
chronic alcohol (more than three drinks a day) or drug abuse; or morbid
obesity (BMI 40 kg/m2) and pregnant women were excluded. Informed
consent was obtained from each participant.
Phenotyping. Details of the study including phenotyping are given elsewhere
(16). At baseline, all study participants were subjected to a comprehensive
program; detailed personal and family history was assessed via standardized
questionnaires. A physical examination included measurement of anthropo-
metric parameters such as BMI, waist circumference, and percentage body fat.
Venous blood was collected after an overnight fast, and plasma samples were
either used immediately for analysis or were stored frozen at 80°C.
Adiponectin concentrations were measured by an enzyme-linked immunosor-
bent assay kit from BioCat (Heidelberg, Germany). A complete lipoprotein
profile including fasting triglycerides, HDL and LDL cholesterol, glucose,
insulin levels, and HbA1c (A1C) were determined. Additional measurements
included blood pressure, intima-media thickness of common carotid arteries
(CCAs) by high resolution B-mode ultrasound, and glucose and insulin levels
post–oral glucose tolerance test (30, 60, and 120 min) in a subgroup of 643
individuals. Subjects were classified as having type 2 diabetes (n  57) if on
hypoglycemic medication or if fasting plasma glucose concentrations ex-
ceeded 126 mg/dl.
Selection of tag SNPs and genotyping. From the known polymorphisms in
the NCBI (National Center for Biotechnology Information) database dbSNP
build 124 (NCBI version 35.1) and in the literature, 53 SNPs of the APM1 gene
with an average distance of 0.7 kb and including SNPs in the promoter and
5-flanking region, the coding and the noncoding regions of the exons have
been identified at the start of this project in February 2003. All of these were
genotyped by restriction enzyme assays in 81 randomly selected subjects from
the 1,770 SAPHIR study participants. From these 53 SNPs, those with a minor
allele frequency (MAF) exceeding 1% and without violation of the Hardy-
Weinberg equilibrium (HWE) were eligible for genotyping in the full sample of
1,770 subjects.
To identify the haplotype tagging SNPs, the eligible SNPs were entered into
the tag SNP program (17) with one known SNP causing an amino acid
exchange (Y111H) being forced into the selection. Briefly, for a given number
of SNPs that can afford to be typed in the full sample, the subset of those SNPs
is derived, which maximizes the R2 (i.e., the proportion of the variance of
haplotypes reconstructed based on the subset compared with the variance of
haplotypes reconstructed based on all SNPs) and thus minimizes the uncer-
tainty in the prediction of the common haplotypes (17). We chose the number
of SNPs to be genotyped in the full sample sufficiently large enough to ensure
an R2 of 95% for common haplotypes (frequency 5%), but we also attempted
a sensible prediction of the rare haplotypes (1–5% frequency) of at least 90%,
where possible. Very rare haplotypes (frequencies 1%) were not the focus of
this investigation.
Genotyping for the 18 haplotype tag SNPs was achieved by primer
extension of multiplex PCR products with detection of the allele-specific prod-
ucts by matrix-assisted laser desorption ionization time-of-flight (MALDI_TOF)
mass spectroscopy (18).
Statistical analysis. Tests for violation of the HWE (2 or exact test
depending on allele frequency) were performed. The relationship between
pairs of SNPs was viewed by the correlation coefficient and Lewontin’s D
(PROC ALLELE, SAS version 9.0, released 2004).
To estimate the association of the variants in the SNPs with changes in
plasma adiponectin concentrations, we applied a general linear regression
model with log(adiponectin  1) as the outcome and each SNP entered
separately in the model as the explanatory variable. For each SNP, we tested
the association of any of the genotypes with adiponectin levels without and
with assuming a trend per copy of the minor allele.
The expected number of copies of each haplotype for all subjects in the full
sample was estimated via the expectation-maximization (E-M) algorithm
(PROC HAPLOTYPE, SAS) based on the tag SNPs. The best-guess number of
haplotypes per subject (i.e., the haplotype pair with the highest probability)
was assigned to each subject. Haplotypes with frequency 1% were collected
into one group (“very rare haplotypes”). For haplotype association analyses,
all haplotypes were included into the regression model testing the association
of each haplotype against the reference group and adjusting for the other
haplotypes. The initial reference group contained the subjects with two copies
of the most common haplotype.
All analyses were adjusted for age and sex. The impact of additional
adjustment for BMI was explored. Because adiponectin concentrations are
known to be modulated by antidiabetic medications, we performed a sensi-
tivity analysis excluding subjects with type 2 diabetes. The proportion of
variance in adiponectin explained by the SNPs (haplotypes) was computed via
R2. A subset of SNPs (haplotypes) maximizing R2, while minimizing the
number of SNPs (haplotypes), was given using a backward selection.
In a secondary analysis, SNP and haplotype association analysis with other
phenotypes correlated with adiponectin concentrations and linked to the
metabolic syndrome were performed.
RESULTS
Selection of tag SNPs and analysis of the block
structure. To provide a systematic investigation of the
APM1 gene polymorphism and their haplotypes, 53 nar-
row-spaced polymorphisms spanning the whole gene were
genotyped in 81 unrelated healthy subjects. A large num-
ber of SNPs were monomorph in the 162 chromosomes,
including six of the eight SNPs with reported amino acid
substitutions. Only one known SNP resulting in an amino
acid substitution in Caucasians (Y111H) was polymorphic,
showing an MAF 1%. Details are given in the online-only
appendix (available from http://diabetes.diabetesjournals.
org). Excluding 1) the 17 monomorph SNPs, 2) one SNP
with severe violation of HWE (P  0.01, 9330), and 3)
three SNPs with a minor allele frequency 0.05 (11423,
1161, and 1245) left 32 SNPs eligible for tag SNP selection,
which were entered into the tag SNP program. The Y111H
was forced into the selection despite the MAF of 3.7% due
to its potentially functional importance.
For analysis of the linkage disequilibrium (LD) block
structure, we used 27 of the 32 SNPs (5 excluded due to
MAF 10%). We observed two LD blocks (D 0.8 for
pairs of consecutive SNPs) with a block boundary be-
tween 2049 and 450 (Fig. 1, upper part). The correla-
tion between the alleles also supported a two-block
structure, as there was no notable correlation between any
SNP of block 1 with a SNP of block 2 (Fig. 1, lower part).
Groups of highly correlated SNPs (r2 0.8) are specified in
the online appendix.
From the 32 SNPs in the tag SNP program, 10 tag SNPs
were selected for block 1, 7 tag SNPs for block 2, and 1
SNP in between (for details, see the online appendix).
Interestingly, selecting the tag SNPs based on a one-block
assumption would have yielded the same SNPs.
Characteristics of the 18 tag SNPs genotyped in 1,770
subjects. The characteristics of the 18 SNPs genotyped in
the full sample of 1,770 subjects are summarized in Table
1. Two SNPs (4522 and 2063) severely violated the
HWE (P  0.0001) and were thus removed from analysis.
The genotyping success rate was 95% except for 18003
(success rate 79%), which was therefore discarded to
assure high-quality data, leaving 15 SNPs in the association
analysis.
Association of APM1 variants with adiponectin con-
centrations in 1,727 subjects. Exclusion of subjects
without measured adiponectin (n  17) or 50% of the
SNPs successfully genotyped (n  26) yielded an analysis
sample of 1,727 subjects. Subject characteristics are given
in Table 2, indicating the excess of men in this study. The
higher age of women and the relatively low diabetes
prevalence in both men and women are due to study
design (see RESEARCH DESIGN AND METHODS). Adiponectin
levels were markedly higher in women. There was no
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trend of decreasing adiponectin by age if differentiated
between the sexes.
Figure 2 summarizes the results from the SNP associa-
tion and gives the P values for overall difference in mean
adiponectin levels in the three or two genotype groups per
SNP. It illustrates significant associations for 11 of the 15
SNPs analyzed. These results remained highly significant,
except for those of Y111H, even when considering the
number of tests performed. Most of these associations
were consistent with an additive inheritance model yield-
ing even stronger P values for association, assuming a
trend per copy (11388, 10066, 8564, 450, 45,
276, and 712).
Note that there were correlated SNPs showing the same
association signal, partly due to their correlation: 1)
14811 and 11388, 2) 10066 and 8564, 3) 45 and
4545, and 4) 276, 712, and 3639. There was not a significant
interaction between 11388 and 10066, and the two
SNPs’ effect estimates were independent and additive.
All analyses were adjusted for age and sex. All associa-
tions were consistent in both men and women when
analyzed separately and when excluding subjects with
type 2 diabetes (n  57). Additional adjustment for BMI
did not markedly change the estimates or the precision,
which excluded the possibility of confounding of the
results by BMI. We also did not find a modulation of the
slope between BMI and adiponectin by the APM1 SNPs
strongly associated with adiponectin levels.
Haplotype analysis. Including all subjects with full infor-
mation on adiponectin concentration and the 15 SNPs
yielded an analysis sample of 1,506 subjects for the
haplotype association analysis. A total of 124 different
haplotypes were reconstructed. We analyzed the 18 hap-
lotypes with frequency 1% and the construct of “very
FIG. 1. LD measures (GOLD plot) for 27 of the 32 SNPs genotyped in 81 subjects with MAF >10%. Top triangle: D (red  1.0, yellow  0.7–0.9,
green  0.4–0.6, blue  0.2–0.3, and black  0.0–0.1). Bottom triangle: R2 (red  1.0, yellow  0.7–0.9, green  0.4–06, blue  0.1–0.3, black 
0.0). Block boundary between 2049 and 450.
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rare haplotypes” (frequency 1%). Subjects with a very
rare haplotype and one copy of the most common haplo-
type were added to the reference group because these
haplotypes exhibited similar mean adiponectin concentra-
tions.
Table 3 summarizes the 18 haplotypes sorted by their
strength of association (i.e., sorted by the change in
adiponectin concentration per copy of the haplotype). Of
the 17 haplotypes tested, 9 showed significant associations
with adiponectin concentrations. It was apparent that the
haplotypes H1 and H2 containing the minor alleles of
14811 and 11388 yielded higher adiponectin concentra-
tions than the reference. The haplotype H4 with only a
minor allele in 11388 also showed rather high adiponec-
tin concentrations. Subjects with the minor allele in
10066 and 8564 exhibited lower adiponectin concen-
trations independent from 11388 or 14811 (P  0.0001,
when testing all haplotypes with G-G against haplotypes
with A-T independent from the haplotypes H1, H2, and
H4).
In block 2, the haplotypes containing ATGGTGG (H12
and H20) or, less strong, ATGGTAG (H17, H19, and H11)
were associated with decreased adiponectin concentra-
tion (e.g., for H12, P  0.0000008). The haplotypes with
GTTATGG as well as AGGATGC showed increased levels.
With the exception of the 450, the SNP associations in
block 2 were explained by these haplotypes. Another
remarkable haplotype is H21, which contains the rare
allele of the amino acid exchange Y111T, otherwise resem-
bles the reference, and is associated with increased adi-
ponectin concentrations.
The variance of adiponectin concentrations (on the
transformed scale) explained by the significantly associ-
ated APM1 SNPs was 8% for men and 7% for women. The
portion of variance explained by all haplotypes was 8% for
men and 9% for women. Note that 18% of the adiponectin
variance was explained by sex alone. The SNPs 11388,
10066, 450, 45, 712, 1242, Y111H, and 3639 make up the
minimal subset of SNPs explaining the largest portion of
adiponectin variance yielded via backward selection. The
haplotypes H12, H20, H8, H16, H9, H21, H15, H4, H2, and
H1 were the respective subset of haplotypes.
Association of adiponectin levels and APM1 variants
with parameters of the metabolic syndrome. The
associations between adiponectin concentrations and pa-
rameters of the metabolic syndrome were strong. We
found one unit of increase in adiponectin concentrations
that was associated with 0.25 BMI points (P  0.0001, by
linear regression adjusted for sex and age). Additionally
adjusting for BMI, one unit of increase in adiponectin
concentrations was associated with 1.3 units in HDL
cholesterol (P  0.0001), 2.9 units in triglycerides (P 
TABLE 1






















1 rs2117985 188035547 18003 5´ region A G 0.79 0.06 0.88 0.11 0.01
2 rs822387 188038739 14811 5´ region T C 0.97 0.09 0.83 0.16 0.01
3 rs860291 188040659 12891 5´ region C T 0.98 0.11 0.80 0.19 0.01
4 rs17300539 188042162 11388 11391,
11379
Promoter G A 0.98 0.10 0.82 0.17 0.01
5 rs182052 188043484 10066 Intron 1 A G 0.98 0.34 0.43 0.47 0.11
6 rs822388 188044986 8564 Intron 1 T G 0.96 0.30 0.49 0.42 0.09
7 rs822391 188046505 7045 Intron 1 T C 0.96 0.18 0.67 0.30 0.03
8 rs822393 188049028 4522 Intron 1 C T 0.98 0.22 0.57 0.43 0.001
9 rs822394 188049430 4120 Intron 1 C A 0.97 0.17 0.69 0.28 0.03
10 rs7649121 188051487 2063 Intron 1 A T 0.98 0.21 0.65 0.27 0.08
11 rs2036373 188052893 657 Intron 1 T G 0.98 0.06 0.89 0.11 0.01
12 rs9882205 188053100 450 Intron 1 G A 0.95 0.29 0.50 0.42 0.08
13 rs2241766 188053594 45 Exon 2 T G 0.99 0.12 0.78 0.21 0.01
14 rs1501299 188053825 276 IVS2G62T Intron 2 G T 0.99 0.30 0.51 0.40 0.10
15 rs3774261 188054261 712 Intron 2 G A 0.94 0.42 0.32 0.51 0.17
16 rs17366743 188054791 1242 Y111H,
T111H,
331TC
Exon 3 T C 0.95 0.03 0.94 0.06 0.001
17 rs4686804 188057188 3639 Exon 3 A G 0.98 0.45 0.30 0.50 0.20
18 rs1063539 188058094 4545 Exon 3 G C 0.97 0.11 0.80 0.19 0.01
*Relating to the NCBI version build 35; †relating to the first position of the translation starting point ATG; ‡portion of successfully typed
subjects; §coded genotypes: 0  homozygote for common allele, 1  heterozygote, and 2  homozygote for rare allele.
TABLE 2




Age (years) 49.2  5.4 56.2  4.3
BMI (kg/m²) 26.9  3.7 26.6  4.7
Adiponectin (	g/ml) 7.1  3.3 11.1  5.3
Diabetes (%) 3.9 2.3
A1C (%) 5.6  0.6 5.7  0.5
Fasting glucose (mg/dl) 94.3  18.3 92.1  17.1
Fasting insulin (	U/ml) 7.6  5.6 7.2  4.2
HDL cholesterol (mg/dl) 55.2  13.4 67.2  16.4
Triglycerides (mg/dl) 136.6  100.5 105.7  52.4
SBP (mmHg) 135.1  12.6 131.3  13.4
DBP (mmHg) 82.4  8.0 81.0  7.6
Data are means  SD unless otherwise indicated. DBP, diastolic
blood pressure; SBP, systolic blood pressure.
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0.0001), 0.0002 units in CCA (P  0.0004), no changes in
blood pressure, 0.05 homeostasis model assessment
index points (P  0.0001), 0.008 units in A1C (P  0.003),
and an 8.8% decrease in the odds of type 2 diabetes (P 
0.008, via logistic regression). For men and women, re-
spectively, adiponectin concentrations explained 5 and 7%
of the variance of BMI, 4 and 8% of waist circumference, 4
and 3% of waist-to-hip ratio, 3 and 5% of percent body fat,
1.1 and 1.6% of A1C, 7 and 6% of the homeostasis model
assessment index, 5 and 12% of post–1-h oral glucose
tolerance test levels, 5 and 6% of fasting triglycerides, 10
and 19% of HDL concentrations, and 1.1 and 1.2% of CCA.
When adjusting for BMI, the explained variances dropped
to 1%.
Figure 3 summarizes the P values from the SNP associ-
ation with the parameters related to the metabolic syn-
drome. Given the large number of tests performed in this
secondary analysis, we would not deem any of the asso-
ciations as statistically significant. The P values 0.01
(indicated by two arrows in the Fig. 3) were found for the
outcome A1C for 7064 and 4120, two correlated SNPs
of the few SNPs not showing association with adiponectin
FIG. 2. SNP association analysis showing differences in mean adiponectin levels (rescaled and adjusted for age and sex) for those subjects with
one copy of the minor allele (o) and for those with two copies (f) compared with zero copies. MAF and P values are also shown. *Testing for
overall differences of means in the genotype groups, adjusted for age and sex.
TABLE 3
Common and rare (frequency 1%) haplotypes across 15 SNPs in 1,506 subjects sorted by change in adiponectin concentrations for
those carrying one copy of the haplotype compared with those with two copies of the most common haplotype (H22) from the general
linear regression model with log(adiponectin  1) as the outcome adjusted for age and sex and with corresponding P value testing









2 3 4 5 6 7 9
Block 2
SNP number:
1 1 1 1 1 1 1 1
1 2 3 4 5 6 7 8
H12 T-C-G-A-T-T-C -T-A-T-G-G-T-G-G 0.023  0.003 2.0 0.0000008
H20 T-C-G-G-G-T-C -T-A-T-G-G-T-G-G 0.019  0.002 0.9 0.04
H17 T-C-G-G-G-C-C -T-A-T-G-G-T-A-G 0.011  0.002 0.6 0.05
H19 T-C-G-G-G-T-C -T-A-T-G-G-T-A-G 0.031  0.003 0.4 0.1
H11 T-C-G-A-T-T-C -T-A-T-G-G-T-A-G 0.066  0.003 0.3 0.1
H23 T-C-G-G-G-T-C -T-G-T-T-A-T-G-G 0.039  0.004 0.1 0.1
H22 T-C-G-G-G-T-C -T-G-T-G-G-T-A-G 0.124  0.006 Reference
H24 T-C-G-G-T-C-A -T-G-T-G-G-T-A-G 0.044  0.004 0 0.1
H26 T-T-G-A-T-C-A -T-G-T-G-G-T-A-G 0.096  0.005 0.3 (0.9) 0.1
H6 T-C-G-A-G-T-C -T-A-T-T-A-T-G-G 0.010  0.002 0.5 0.1
H8 T-C-G-A-T-T-C -G-G-T-T-A-T-G-G 0.054  0.004 0.6 0.06
H16 T-C-G-A-T-T-C -T-G-T-T-A-T-G-G 0.100  0.005 0.8 (2.6) 0.0005
H9 T-C-G-A-T-T-C -T-A-G-G-A-T-G-C 0.066  0.005 0.8 0.007
H21 T-C-G-G-G-T-C -T-G-T-G-G-C-A-G 0.025  0.003 0.9 0.03
H15 T-C-G-A-T-T-C -T-G-T-G-G-T-A-G 0.093  0.005 0.9 (1.5) 0.0003
H4 T-C-A-A-T-T-C -T-G-T-T-A-T-G-G 0.019  0.002 1.6 0.002
H2 C-C-A-A-T-T-C -T-G-T-T-A-T-G-G 0.053  0.004 1.8 0.00000002
H1 C-C-A-A-T-T-C -T-A-G-G-A-T-G-C 0.016  0.002 2.5 0.00002
*Expected haplotype frequency and SE; †assuming a trend per copy, adjusted for age and sex.
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concentrations. A P value of 0.02 was found for the
association between 276 with HDL cholesterol (60.7,
59.6, and 58.3 ml/mg), which showed a trend per copy of
the minor allele consistent with the trend in adiponectin
concentrations (compare with Fig. 2). Further, the direc-
tion of the changes in parameters of body composition
(BMI, waist, and percent body fat), even if not significant,
was as expected from the SNP association with adiponec-
tin levels for the SNPs 11388 (waist 94.8, 93.8, and 91.0
cm; BMI 26.8, 26.6, and 25.1 kg/m2; and percent body fat
19.3, 18.1, and 18.7% for 0, 1, or 2 copies of the minor allele,
respectively) and Y111H (waist 94.8 and 92.4 cm, BMI 26.9
and 26.2 kg/m2, and percent body fat 19.1 and 18.1 for 0 or
1 minor allele).
DISCUSSION
We have systematically analyzed fine-mapped SNPs cov-
ering the full range of APM1 and underlying haplotypes in
a large group of 1,727 healthy Caucasians. We observed a
two-block structure of the APM1 gene as well as many and
particularly strong associations of SNPs and haplotypes
with adiponectin concentrations. We have not found a
significant association of the APM1 gene with parameters
of the metabolic syndrome.
Finemapping, block structure, haplotypes, and gene-
alogy. To date, none of the reported studies have applied
the approach of fine mapping in combination with select-
ing haplotype tagging SNPs to represent the underlying
haplotypes spanning the whole gene. Menzaghi et al. (19)
and Gu et al. (20) described four tag SNPs for the nine
common SNPs described by Vasseur et al. (21) in 2002. In
contrast, we based our tag SNP selection on genotyping 53
known SNPs in 81 subjects from our study sample and
selecting haplotype tagging SNPs to sufficiently predict all
haplotypes with frequency 1%. This resulted in genotyp-
ing 18 tag SNPs in 1,770 subjects. By this two-step ap-
proach described by Stram et al. (17), we have yielded
optimal haplotype prediction while minimizing genotyping
resources.
LD blocks define recombination-free regions and delin-
eate potential causal regions for an observed association
signal (22). Gibson and Froguel (23) reported the APM1 as
a locus of high haplotype diversity and estimated the
population recombination rate to be 0.092, which is high
compared with the average value of 0.0004 (24). Our data
on the 27 SNPs with MAF 10% of the prescreening in 81
subjects suggest a two-block structure of APM1 gene with
a block boundary between 2049 and 450 (D  0.16)
(Fig. 1). Therefore, part of the high recombination rate in
APM1 may be explained by a recombination “hot spot”
between the two blocks. Very recently, Sutton et al. (25)
described a two-block structure of APM1 in 91 Hispanics
from obese families with a block boundary between 7950
and 4120. Such a shift in block boundaries was observed
previously between European populations, particularly
between South and Central Europeans (26).
Our haplotype analysis showed clear stratification of
adiponectin concentrations suggesting that either the com-
bination of certain alleles or rare latent mutations picked
up by the respective haplotypes may be part of the
functional genetic mechanism modulating circulating adi-
ponectin levels (27). In block 1, the promoter SNPs
11388 and 11374 (highly correlated to the analyzed
10066) seem to act independently and additively on
adiponectin concentrations, which was underscored by a
between-SNP interaction model as well as by haplotype
association analysis. In block 2, the direct impact of one
SNP alone was more difficult to distinguish because loci
45, 276, 712, 3639, and 4545 were moderately correlated
and one could have picked up part of the signal of the
other in the SNP association, which calls for haplotype
analysis. Functional effects have been speculated for the
FIG. 3. P values from SNP association with all quantitative phenotypes repeating the P values from the association with adiponectin
concentrations (compare with Fig. 2).
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promoter SNPs as well as the rare mutations in the coding
region of exon 3 (21,28). This speculation would thus be
supported by our finding of the two-block structure,
indicating at least two causal regions of the APM1 gene
because the promoter SNPs located in block 1 and the
haplotypes in block 2 may represent latent causal muta-
tions in the relevant exons.
Based on a two-block assumption, our haplotypes sug-
gested a possible genealogy, as depicted in Fig. 4. For
block 1, the haplotype TCAAT is just one mutation away
from the wild-type TCGAT; the haplotype CCAAT is two
mutations away from the wild type. Both haplotypes were
associated with increased levels of adiponectin in a dose-
dependent manner. Similarly, for block 2, the haplotypes
ATGGTAG (one mutation) and ATGGTGG (two mutations
away) account for decreased levels and are also dose
dependent. It was most intriguing that the “bad haplo-
types” tended to gather on one branch and the “good” ones
on another.
Strong association of APM1 variants with adiponec-
tin concentrations. Overall, we found more associations
with markedly smaller P values than those published thus
far. A reason for the exceptionally clear associations might
be the large sample size and the fact that the SAPHIR
study involves particularly healthy subjects, all working
(“healthy worker effect”) (29) and without symptomatic
cardiovascular disease (exclusion criterion). We speculate
that in healthy subjects, the primary genetic effect of
APM1 variants on adiponectin concentrations is better
detected as no counter regulations from disease processes
occurred (30–32). Our findings are in line with associa-
tions in French obese and type 2 diabetic subjects re-
ported by Vasseur et al. (21) in one of the largest studies to
date, analyzing 922 subjects with measured adiponectin
levels. Our findings extend their results by showing more
and stronger associations and by underscoring that the
modulation of adiponectin concentrations from variants in
the APM1 is not merely a concomitant effect of obesity or
type 2 diabetes.
Reviewing the literature on the APM1 gene revealed
conflicting results on the presence and direction of asso-
ciations of adiponectin levels with particular SNPs. Fur-
thermore, it was difficult to judge whether the reported
SNP associations with parameters of the metabolic syn-
drome were consistent with the direction of their associ-
ation with adiponectin concentrations; most reported
studies were case-control studies comparing patients with
type 2 diabetes (20,21,23,33–36), hyperglycemia (20,37),
coronary artery disease (34,38,39), or obesity (40) with
control subjects. Many of these studies have measured
adiponectin levels only, if at all, in a small subsample of
subjects. Only a few studies (21,23,41) have apparently
aimed to investigate adiponectin concentrations as the
primary outcome. An overview of the studies on APM1
with adiponectin measured in at least 100 unrelated indi-
viduals is provided in Table 4. There were only five studies
(19,21,23,41,42) including 500 subjects with adiponectin
levels measured. Two of those (41,42) involved different
ethnicities than in our study, and only one study (19)
investigated healthy Caucasian subjects.
Association with components of the metabolic syn-
drome. There is strong evidence in the literature linking
low levels of adiponectin with the development of the
metabolic syndrome as well as with its consequences, type
2 diabetes and coronary artery disease (7,43). Adiponectin
is even deemed a potential therapeutic agent (44). Animal
models have shown that adiponectin is a potent insulin
enhancer, regulating energy homeostasis and glucose tol-
erance (9–11). Mice fed a high-fat diet experienced pro-
found weight loss when chronically treated with a
proteolytic fragment of adiponectin (10). However, the
direct contribution of the APM1 variant-induced changes
of adiponectin levels on measures of adiposity, lipids, or
parameters of insulin resistance and the role of type 2
diabetes in humans is less clear.
Although we found strong associations of adiponectin
plasma concentrations with type 2 diabetes and several
parameters of the metabolic syndrome, we could not find
significant associations of the APM1 gene variants with
these phenotypes. This might be explained by the obser-
vation that the APM1 gene variants in our data explained
8% of adiponectin concentration variance and adiponec-
tin concentrations explained 1–10% of the variance of the
parameters of the metabolic syndrome. Considering that
this leaves a maximum of 1% of the metabolic syndrome
parameter variance directly explained by the APM1, it
could well be that there is a causative link; in this case it
would not be surprising that we could not detect an
association of the APM1 gene variants with these pheno-
types. This underscores that studying gene products as
intermediate phenotypes closely related to the gene itself
might be more fruitful than concentrating on phenotypes
further down the pathway.
Conclusion. The present study on the APM1 gene is the
first one exceeding 1,500 subjects with measured adi-
ponectin levels. The study sample represents a particularly
healthy Caucasian population. Further, the APM1 gene
was, to our knowledge, never analyzed with the approach
of similarly narrow dense SNPs covering the full gene.
These prerequisites—large sample, healthy population,
and fine-mapped SNPs—enabled the discovery of many
FIG. 4. Haplotypes from Table 3 in block 1 (A) and block 2 (B) with the
line indicating the distance between two haplotypes of one mutation
and a line with three marks indicating three mutations (haplotype
frequency in parentheses). Shown is the change in circulating adi-
ponectin for subjects having one copy of the haplotype and the
corresponding P value if P < 0.1 is given.
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strong and highly significant associations of APM1 gene
markers with circulating adiponectin, thus clarifying a
primary association of the gene variants not just concom-
itant with disease and shedding some light on the two-
block architecture and genealogy of the haplotypes.
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